Drug Profile


Alternative Names: 2118436; DRB 436; GSK 2118436A; GSK-2118436; Tafinlar

Latest Information Update: 09 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator GlaxoSmithKline
  • Developer GlaxoSmithKline; Novartis; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Fluorobenzenes; Pyrimidines; Small molecules; Sulfonamides; Thiazoles
  • Mechanism of Action Protein kinase inhibitors; Proto oncogene protein b raf inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Malignant melanoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Malignant melanoma
  • Registered Non-small cell lung cancer
  • Phase II Brain metastases; Cancer
  • Phase I/II Colorectal cancer; Solid tumours

Most Recent Events

  • 11 Sep 2017 Interim efficacy and adverse events data from the phase III COMBI-AD trial in Malignant-melanoma presented at the 42nd Congress of European Society for Medical Oncology (ESMO-2017)
  • 11 Sep 2017 Updated efficacy data from a phase II trial in Non-small cell lung cancer presented at the 42nd Congress of European Society for Medical Oncology (ESMO-2017)
  • 22 Jun 2017 Registered for Non-small cell lung cancer (Combination therapy, Late-stage disease, Metastatic disease) in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top